Form 4: Beta Bionics CCO Executes Tax-Related Stock Sale

Chief Commercial Officer Mark Hopman sold 5,329 shares of Beta Bionics to satisfy tax withholding obligations.

Summary

• Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., sold 5,329 shares of common stock.
• The transaction occurred on June 2, 2026.
• The shares were sold at a weighted average price of $12.6071 per share, with a price range between $12.30 and $12.93.
• Following the transaction, the reporting person retains beneficial ownership of 130,887 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely for tax compliance purposes rather than a discretionary divestment.

Positives

• The sale was non-discretionary, specifically executed to cover tax withholding obligations related to the vesting of restricted stock units.

Negatives

• Reduction in the direct equity stake held by a key executive.

Risks

• Market volatility affecting the value of remaining equity holdings.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that tax-related sell-to-cover transactions are standard administrative procedures for executives and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for equity-based compensation vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover.

Next Steps

• None indicated.

Key Dates

Keywords

Beta Bionics, BBNX, Insider Trading, Form 4, Executive Compensation, Tax Withholding